Golden Years Home Care Continues Mission to Transform Lives with Premier Senior Home Care in San Diego, CA
Golden Years Home Care reaffirms its mission to provide premier senior home care in San Diego, CA, helping seniors age with dignity and comfort at home. Through personalized care plans, compassionate companionship, and assistance with daily needs, the agency supports independence while easing the burden on families. Highly trained caregivers deliver safety, emotional support, and peace of mind, ensuring seniors enjoy a higher quality of life in familiar surroundings.
San Diego, CA - Golden Years Home Care today reaffirms its unwavering commitment to the senior community of San Diego. Under the leadership of Ken Ballard, the agency continues its mission to transform the lives of elderly residents and their families through dedicated and personalized in-home care services. This ongoing initiative addresses the critical need for reliable support, allowing seniors to age with dignity and comfort in their own homes.
As the population of seniors grows, many families find themselves navigating the complexities of providing adequate care for their aging loved ones. The desire for seniors to remain in a familiar, cherished environment is often met with the challenge of ensuring their safety, health, and well-being. Golden Years Home Care steps into this gap, offering a structured yet compassionate solution that alleviates the pressure on family caregivers and enhances the quality of life for seniors.
One of the most significant benefits of the services provided by Golden Years Home Care is the profoundly personalized approach. Recognizing that every individual has unique needs and preferences, the agency develops customized care plans in close consultation with the senior and their family. This tailored strategy for senior care at home in San Diego, CA ensures that clients maintain their independence and daily routines while receiving the precise level of support they require, from companionship and meal preparation to mobility assistance.
Furthermore, the service provides invaluable peace of mind for families. Entrusting the care of a loved one to a professional is a major decision, and Golden Years Home Care addresses this with a team of highly trained, vetted, and compassionate caregivers. Families can rest assured that their loved ones are not only safe but are also benefiting from social interaction and emotional support, combating the loneliness and isolation that can often affect seniors. This comprehensive approach is the hallmark of quality Senior Home Care in San Diego, CA.
"Our goal has always been to build a support system that feels like family," said Ken Ballard, founder of Golden Years Home Care. "We see the challenges families face every day, and we want them to know they are not alone in this journey. Our team is here to provide the compassionate, professional care that allows their loved ones to age gracefully and safely in the comfort of their own home."
Golden Years Home Care continues to be a pillar of support in the San Diego community, dedicated to fostering independence and delivering exceptional care. The agency's mission is rooted in the belief that every senior deserves to live a fulfilling and dignified life, regardless of age or health challenges.
For more information about Golden Years Home Care and their senior home care in San Diego, CA, please visit their website at https://goldenyearshomecare.com/san-diego-ca.
About Golden Years Home Care:
Golden Years Home Care is a leading provider of senior care at home in San Diego, CA. Founded on the core principles of compassion, dignity, and respect, the agency is dedicated to helping seniors live independently and safely in the comfort of their own homes. By offering customized care plans, their team of highly trained and vetted caregivers is committed to enhancing the quality of life for every client. Golden Years Home Care serves as a trusted partner for families, delivering peace of mind and ensuring their loved ones receive the exceptional support they deserve.
Media Contact
Company Name: Golden Years Home Care (San Diego, CA)
Contact Person: Ken Ballard
Email: Send Email
Phone: (916) 333-0383
Address: 301 SPRUCE ST, STE 101
City: San Diego
State: California 92103-5626
Country: United States
Website: https://goldenyearshomecare.com/san-diego-ca/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
6 hours ago
- Globe and Mail
Profound Medical Posts Wider Loss in Q2
Key Points Revenue (GAAP) declined slightly year over year to $2.2 million in Q2 2025, missing GAAP revenue estimates by 32.3% on delayed capital sales. Operating expenses (GAAP) climbed approximately 65.8%, pushing net loss (GAAP) to $15.7 million, Net loss for the quarter ended June 30, 2025, increased approximately 127.5% year over year. Management reiterated its annual revenue growth target of 70–75% year-over-year in 2025; with the outlook relying on a sharp second-half rebound in 2025. These 10 stocks could mint the next wave of millionaires › Profound Medical (NASDAQ:PROF), a medical technology company specializing in minimally invasive prostate therapies, reported its GAAP financial results for Q2 2025 on August 14, 2025. The company reported no GAAP revenue growth compared to the prior-year period, with total GAAP revenue of $2.2 million, well below analysts' expectations of $3.25 million. The company's net loss widened to $15.7 million, or $0.52 per share (GAAP). The quarter saw higher operating costs and a delay in capital equipment deals, contributing to weaker-than-expected performance. Despite these headwinds, management reaffirmed its full-year 2025 guidance for strong revenue growth in the approximate range of 70% to 75% year-over-year, but the results highlight ongoing execution risks. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Business Snapshot and Strategic Priorities Profound Medical develops technologies for image-guided, minimally invasive treatments for prostate diseases. Its flagship TULSA-PRO system enables physicians to ablate (destroy) prostate tissue using real-time magnetic resonance imaging (MRI) and high-intensity ultrasound. The Sonalleve system, another platform, is used for the treatment of uterine fibroids and other conditions with focused ultrasound. The company's near-term focus is to expand adoption of its TULSA-PRO system in the U.S. and abroad, leveraging recent regulatory wins and reimbursement changes. Key to success are continued clinical validation, conversion of sales pipeline opportunities into system placements, and growing a reliable stream of recurring revenue from consumables, leases, and services tied to each installed system. Profound Medical's ability to manage costs and extend its cash runway until recurring revenue can support operations is also critical, given its current reliance on external funding. Quarter in Review: Operations and Financials The company experienced a stalled top line, reporting $2.2 million in GAAP revenue for Q2 2025—virtually unchanged from the prior year and substantially below consensus estimates. This GAAP revenue miss was attributed to short-term delays in closing several capital sales for TULSA-PRO systems. According to management, had these deals been completed during the quarter, revenue would have topped $3 million. Recurring revenue from procedures, disposables, and service grew by 6.9%, rising from $1.46 million in Q2 2024 to $1.56 million in Q2 2025 (GAAP), and accounted for most of the total revenue. Sales of capital equipment dropped slightly, reflecting the postponed deals. Meanwhile, procedure volumes continued to rise at existing customer sites, with 'same-store' utilization up 10% from Q1 2025. The sales pipeline for new TULSA-PRO system placements increased, with 80 systems in advanced negotiation stages as of quarter end. This suggests strong demand, but actual conversion of this pipeline into revenue remains a known risk. The company's product portfolio saw notable milestones: The TULSA-AI Volume Reduction Module—an artificial intelligence-based add-on for treating benign prostatic hyperplasia (BPH)—completed its first commercial procedure and soft-launched at five sites, with a full release planned for the fourth quarter of 2025. Profound Medical also continued to develop 'TULSA+,' a program to bundle TULSA-PRO with MRI scanners from Siemens, with commercial sales expected to launch before the end of 2025. The TULSA-PRO system received important clinical validation during the period. Initial data from the CAPTAIN randomized trial showed the device provides a statistically significant improvement in post-operative experience compared to traditional robotic prostatectomy—patients experienced no blood loss, faster recovery, and less pain. This data gives the product a competitive edge and is being rolled out at key clinical meetings to boost awareness and drive adoption. Gross margin (GAAP) improved to 73%, up from 64% a year earlier in Q2 2025, reflecting more efficient manufacturing. However, the gain could not offset a jump in operating costs, which rose approximately 65.6% year-over-year to $15.4 million (GAAP). Research and development (R&D) spending rose to $6.1 million (GAAP). Selling, general, and administrative (SG&A) costs (GAAP) climbed to $9.3 million as Profound Medical increased headcount and built up commercial infrastructure to support market expansion and the CAPTAIN trial. The net loss (GAAP) widened to $15.7 million, up from $6.9 million in Q2 2024. Higher expenses with no corresponding revenue growth drove this result. Profound Medical ended Q2 2025 with $35.2 million in cash (GAAP), down from $54.9 million at December 31, 2024 (GAAP). Inventory levels also increased to $8.35 million (GAAP) as of quarter end, but the results highlight ongoing execution risks. Looking Forward For the remainder of FY2025, management maintained its guidance for total annual revenue growth of 70–75%, despite the weak first-half result. Achieving this will depend on a sharp ramp-up in capital systems sales and recurring revenue in the second half of 2025. This reflects management's expectation for a stronger pipeline conversion as new reimbursement codes, clinical data, and product launches come to fruition. The company stated that a 'back-end loaded' revenue profile is anticipated for 2025, consistent with the shift toward upfront capital equipment sales. Meeting these ambitious targets will require improved execution and more predictable closing of sales, as well as continued clinical advocacy of the TULSA-PRO platform. Investors should monitor: the rate at which pipeline deals materialize into revenue; expense growth relative to sales; and ongoing improvements in the balance of recurring versus one-time capital sales. PROF does not currently pay a dividend. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,062%* — a market-crushing outperformance compared to 185% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 13, 2025 JesterAI is a Foolish AI, based on a variety of Large Language Models (LLMs) and proprietary Motley Fool systems. All articles published by JesterAI are reviewed by our editorial team, and The Motley Fool takes ultimate responsibility for the content of this article. JesterAI cannot own stocks and so it has no positions in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Globe and Mail
6 hours ago
- Globe and Mail
Piper Sandler Sticks to Their Hold Rating for Oscar Health (OSCR)
Piper Sandler analyst Jessica Tassan maintained a Hold rating on Oscar Health yesterday and set a price target of $13.00. The company's shares closed yesterday at $14.93. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Tassan is an analyst with an average return of -6.8% and a 36.08% success rate. Tassan covers the Healthcare sector, focusing on stocks such as Oscar Health, Omnicell, and UnitedHealth. In addition to Piper Sandler, Oscar Health also received a Hold from TR | OpenAI – 4o's Soren Coverra in a report issued on August 8. However, yesterday, Wells Fargo maintained a Sell rating on Oscar Health (NYSE: OSCR). Based on Oscar Health's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $3.05 billion and a net profit of $275.27 million. In comparison, last year the company earned a revenue of $2.14 billion and had a net profit of $177.37 million Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of OSCR in relation to earlier this year.
Globe and Mail
7 hours ago
- Globe and Mail
CYSM Showcases Exclusive Technology That Makes Its Body Shapers Different in Wake of Rise of Comfortable Shapewear
CYSM Shapers is a US-based body shaper manufacturer with over one million items sold in 30+ years of operation. As comfortable shapewear is taking over the market, CYSM Shapers has proudly showcased the technology that makes its products stand out among the competitors. "Body shapers are no longer these cumbersome, uncomfortable things that you only wear on a special night out and hope you can make it through the discomfort in one piece," a company representative stated. "We have been vocal proponents of daily shapewear for many years, and we put our work behind our stance." It all starts with advanced shapewear engineering, the representative added, saying that all CYSM Premium Shapewear is certified under the OEKO-TEX Standard 100. "That's a globally recognized testing and certification system for textiles. The certification process is rigorous, for sure, but it makes sure that our shapewear meets the highest standards for safety and quality. It shows our commitment to trustworthy shapewear that blends fashion with health for everyday needs." Under this standard, CYSM is classified as Class II, meaning safe for prolonged skin contact but also well-suited for post-surgery recovery. "It's interesting," the rep added. "Our journey started over 30 years ago and we were initially 100 percent focused on crafting shapewear post-surgery recovery. We never gave up on that, we just expanded." However, the rep added that the BIO Therapy Technology played a pivotal role in transforming CYSM Shapers into full-on daily shapewear that is safe and comfortable to use throughout the day. The way BIO Therapy works is that it infuses microcapsules with marine algae onto the skin. The microcapsules are released upon skin contact, and they help restore elasticity, firmness, and beauty of the skin. They also grant antibacterial protection through prevention of bacteria and fungal growth. This promotes healthy skin and positively affects post-surgery recovery. Finally, the breathable fabric regulates the temperature and reduces moisture to keep the skin feeling fresh. "It's not just your figure, it's about your comfort," the company rep added before showcasing the multi-layered construction of the CYSM fabric. It features a high-compression outer layer, medium compression in the inner layer, and soft fabric at the bottom to keep the skin fresh and irritation-free. When it comes to the fabric quality, the team stated: "At CYSM Shapewear, we prioritize top-quality products made from the finest materials. Our fabric is soft, hypoallergenic, and prevents irritation, which makes it ideal for long-term wear." The premium-tier materials used in CYSM Premium Shapers promote airflow and moisture control. They create a microclimate for all-day comfort and freshness. The material also maintains its compression and its shape after stretching to achieve an effective fit. The shapers are made to withstand frequent washing without losing shape or compression. The team added that their ultimate goal is for their customers to feel confident and not covered up. "Stop hiding your body with oversized clothes," they said. "CYSM's tummy control shapewear gently shapes with soft, high-quality fabrics and smart compression—so you can confidently show off your figure." In terms of sizing, the company maintains an inclusive approach and offers sizes from S to 3XL. Compression levels also vary, and can be adjusted between Medium, Heavy, and Ultra control for the highest degree of compression and sculpting. A satisfied customer named Alejandra wrote in her 5-star review of one of the best-selling CYSM shapers: "Great, well-made tummy control body shaper. The material is very high-end, great material. Overall, I highly recommend this product!" Beyond traditional shapewear, CYSM also offers post-surgery products and waist trainers. The company's Waist Trainer lineup focuses on providing the same compression benefits while also boosting the wearer's physical performance for better workout results. The Trainers also improve posture for extra benefits. More information about CYSM Shapers, the company's history, technology, and the full product lineup, can all be found on the official website. Media Contact Company Name: CYSM Shapers Contact Person: CYSM Team Email: Send Email Phone: +13235861600 Address: 5807 Pacific Blvd City: Huntington Park State: CA 90255 Country: United States Website:
